288 related articles for article (PubMed ID: 11748733)
1. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.
Varrone A; Marek KL; Jennings D; Innis RB; Seibyl JP
Mov Disord; 2001 Nov; 16(6):1023-32. PubMed ID: 11748733
[TBL] [Abstract][Full Text] [Related]
2. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
[TBL] [Abstract][Full Text] [Related]
3. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
[TBL] [Abstract][Full Text] [Related]
4. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
[TBL] [Abstract][Full Text] [Related]
5. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
Kim SE; Lee WY; Choe YS; Kim JH
Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
[TBL] [Abstract][Full Text] [Related]
6. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
[TBL] [Abstract][Full Text] [Related]
7. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Change of DAT SPECT in Parkinson's Disease and Multiple System Atrophy.
Sakakibara S; Hashimoto R; Katayama T; Kenjyo M; Yokokawa Y; Saito Y; Hirakawa A; Ito M; Nakamura T; Hara K; Hashizume A; Aiba I; Inukai A; Katsuno M
J Parkinsons Dis; 2020; 10(1):123-130. PubMed ID: 31707374
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-TRODAT-1 imaging of multiple system atrophy.
Lu CS; Weng YH; Chen MC; Chen RS; Tzen KY; Wey SP; Ting G; Chang HC; Yen TC
J Nucl Med; 2004 Jan; 45(1):49-55. PubMed ID: 14734673
[TBL] [Abstract][Full Text] [Related]
10. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
[TBL] [Abstract][Full Text] [Related]
11. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
[TBL] [Abstract][Full Text] [Related]
12. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.
Swanson RL; Newberg AB; Acton PD; Siderowf A; Wintering N; Alavi A; Mozley PD; Plossl K; Udeshi M; Hurtig H
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):302-7. PubMed ID: 15791439
[TBL] [Abstract][Full Text] [Related]
13. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
[TBL] [Abstract][Full Text] [Related]
14. [Dopamine transporter SPECT in patients with Parkinson's disease].
Hamano T; Tsuchida T; Hirayama M; Fujiyama J; Mutoh T; Yonekura Y; Kuriyama M
Kaku Igaku; 2000 Mar; 37(2):125-9. PubMed ID: 10783572
[TBL] [Abstract][Full Text] [Related]
15. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
[TBL] [Abstract][Full Text] [Related]
16. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
[TBL] [Abstract][Full Text] [Related]
17. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
Parkinson Study Group
JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
[TBL] [Abstract][Full Text] [Related]
18. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
[TBL] [Abstract][Full Text] [Related]
19. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
20. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
Pirker W; Asenbaum S; Bencsits G; Prayer D; Gerschlager W; Deecke L; Brücke T
Mov Disord; 2000 Nov; 15(6):1158-67. PubMed ID: 11104200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
